Cyrus’s CTO Javier Castellanos was featured in a story on Chile Global, the website of a Chilean entrepeneur’s group focused on connecting Chileans who are making a big impact abroad with their home country. The article describes Javier’s path from being a Biochemistry undergrad in Chile to co-founding Cyrus Biotechnology. It focuses on the key role his work in Prof. David Baker’s lab played in growing Javier’s interest in protein design, and how Cyrus was conceptualized as a mission to bring more powerful tools to users outside of academia. The full article is below, and is in Spanish, but Google Translate does a decent job of translating it automatically.
Scientists in the UW IPD and David Baker’s lab there have been designing mini-proteins up to 120 residues over the last few years, in a slew of exciting research papers in protein design. Now for the first time they’ve designed short cyclic peptides in the range 18-47 residues — constrained for example by N to C terminal cyclization. Cyclic peptides in nature have evolved into a wide variety of binding modalities, and they are therefore of great interest as drug candidates. Twelve cyclic peptides are designed and have their structures confirmed by experimental methods in this tour de force manuscript. Cyrus co-founder Yifan Song is a co-author on this combined computational and wet lab work.
Read the original article at Nature’s website:
Seattle, WA, April 1 2016. Cyrus Biotechnology is proud to announce a major step forward in computer biochemistry, the ROSVAC-2, an industrial-strength minicomputer custom-designed for simulations of biological molecules, with an astonishingly small 2000 sq ft. footprint, capable of over 5 simultaneous protein amino acid sequence calculations per annum.
Data is input into ROSVAC-2 using our proprietary PROTTAPES, custom-designed tape input and storage appliances capable of over 100 bytes per second data storage, recording an atomic protein structure in mere hours! ROSVAC-2 displays protein cartoon structures in beautiful 128×128 black and white pixels (ROSVAC-2 operator control booth pictured below). ROSVAC-2 requires a minimal staff of 5 technicians and 3 data entry staff, along with 1 glassblower and a part-time blacksmith for routine repairs.
“The best part is how easy it is to use! I just startup the generator, rebuild the broken vacuum tubes, initiate startup procedures, finalize boot loading, set switches 7 through 1028 and then press the red button and turn the key” said ROSVAC-2 beta tester Steve Smith of the USAF. “Three months later I have results I can use.”.
“Why run on the cloud when you can have a ROSVAC-2 installed on-site in a dedicated room for only a few million bucks?”, says user John Jacobs at General Electric, “last time I checked its not raining!”.
Cyrus is taking orders for ROSVAC-2 now! Installation at your facility complete in 12-18 months. Prices start at only $15 million, and support contracts are available. Cyrus is also offering a 6 month training course at ROS-U for corporate technicians.
Thanks for reading! If it is not already clear, Cyrus is not really launching a ROSVAC-2, but is in beta testing for our best-in-class cloud-based protein modeling and design tool, Cyrus Bench based on Rosetta, with general release in mid 2016. Contact us at firstname.lastname@example.org if you would like to learn more.
Cyrus offers an easy-to-use cloud pipeline using SparksX software package to accelerate drug development
Seattle, and Indianapolis, October 8, 2015 – Cyrus Biotechnology has signed a software licensing agreement with Indiana University Research and Technology Corporation (IURTC) at Indiana University (IU) to commercialize the SparksX software package developed at the lab of former IU professor Yaoqi Zhou at the Indianapolis campus.
Cyrus offers a highly automated protein structure prediction and design software-as-a-service (SaaS) package, “Cyrus Bench”, for both bench scientists and computational biologists/chemists.
SparksX, combined with Rosetta from David Baker’s lab at the University of Washington (UW) and licensed to Cyrus, leads the competition in protein homology modeling, both in the biennial CASP and weekly CAMEO “blinded” competitions.
SparksX, developed by Zhou and his team, recognizes protein folds and identifies “deep” (difficult to detect) protein sequence similarity, or homology, better than any other software package, winning first place in CASP 6.
The Cyrus founding team brings decades of protein modeling and high-performance computing experience, with UW Professor David Baker, scientific advisor, Lucas Nivon, CEO, Yifan Song, CSO, Javier Castellanos, CTO.
“As a powerful tool for molecular modeling, SparksX is positioned to help further establish Cyrus as a leader in the drug development space. They have a suite of products that were originally developed through academic work across multiple universities, and Cyrus is a fine example of how startup ventures can further the impact of such research and translate these developments into the marketplace. We are delighted to partner with the Cyrus team to bring the SparksX software to market”, said Marie Kerbeshian, VP of Technology Commercialization at IURTC.
Cyrus is thrilled to announce the addition of Rosario Caltabiano to our Executive Team as Executive VP of Sales.
Rosario is a fervent customer advocate and successful professional with a high level of integrity. He brings over fifteen years of experience in sales and management with a consistent and successful growth track record, having worked in small and large companies, including Accelrys, IBM, and Interactive Supercomputing. His strong focus on bringing computationally intensive, scientific software to R&D organizations is a winning formula for Cyrus Biotechnology and its valued customers.
At Accelrys, a leading provider of enterprise scientific software to the Biotech, Chemical and Pharmaceutical industries, Rosario more than doubled his business in just three years, and was the top performer company-wide in 2012. At Interactive Supercomputing, a start-up offering parallel computing software, Rosario’s team acquired 50 new US customers in just two years. At IBM, Alliant Computer Systems and SGI, Rosario had strong exposure to in-silico molecular simulation software and collaborated with scientists and researchers in various technical and sales roles.
He earned a Master’s Degree, Summa Cum Laude, in Electrical Engineering from Universita` degli Studi di Napoli, Italy.
Cyrus Biotech’s CEO, Lucas Nivon, was interviewed at the WBBA’s LSINW, talking about software opportunities in the cloud for the Biotech and Pharma industries.
Cyrus Biotech CEO Lucas Nivon presented a summary of the Cyrus software package’s features and target use cases at the Life Sciences Innovation Northwest (LSINW) on July 1, 2015. Cyrus CEO Lucas Nivon at LSINW
Puget Sound Business Journal has published a concise summary of Cyrus’ software and our mission — to accelerate drug development with powerful new software deployed on the cloud. Puget Sound Business Journal Article.
Geekwire profiles our licensing of Rosetta software and our plans to develop an easy-to-use version of Rosetta aimed at working scientists. Geekwire Article